Take heed to this text
The Meals and Drug Administration (FDA) deemed a recall of the Asensus Surgical Senhance surgical robotic as Class I, essentially the most severe type. Asensus recalled its Senhance system as a result of malfunctions inflicting unintended motion of the robotically-assisted surgical machine.
The difficulty offered itself as an uncontrolled arm movement of the laparoscope instrument actuator (LI). On this case, the LIA rotated constantly in a single route after the surgeon eliminated the engagement of teleoperation on the system.
The corporate designed Senhance with emergency cease capabilities to cease this challenge if noticed. Asensus reported no affected person impression or hurt as a result of this challenge up to now. Nonetheless, the potential for crucial tissue trauma stays attainable.
Affected Senhance programs embrace catalog numbers X9007708, X9007696 and X9007707. The recall impacts 5 units within the U.S., distributed between April 13, 2023, and Sept. 7, 2023. Asensus initiated the recall on Sept. 15, 2023, based on an FDA notice.
The corporate instructed affected prospects to stop use of Senhance till the workforce up to date the machine’s software program to model 2.7.5.
Asensus designed Senhance to be used usually laparoscopic and laparoscopic gynecological procedures. The corporate received FDA clearance for the system in 2017. Since then, it secured expanded indications, offers with Google and Nvidia, and hospital placements in Japan, Germany, Switzerland and Russia.
Senhance turned the primary and solely digital laparoscopic surgical procedure system for youngsters when the FDA cleared its pediatric indication in March.
The system’s 3 mm devices are the world’s smallest amongst surgical robotics platforms — and people devices are reusable. Asensus additionally designed Senhance with a 5 mm digicam scope, haptic suggestions, eye-tracking digicam management and 3D visualization. The system makes use of machine studying and augmented actuality to help surgeons throughout procedures.
Asensus unveiled its next-generation surgical robotic, Luna, in February 2023. The system includes a next-generation surgical platform and devices, plus real-time intraoperative scientific intelligence. Earlier this week, Asensus announced it struck a deal with Flex for design and superior manufacturing providers for Luna. Asensus has stated it’s targeting FDA clearance for Luna in 2025.
Editor’s Word: This text first appeared on sister web site MassDevice.